| Description | β-Aminoarteether (SM934 free base), an orally active derivative of Artemisinin, serves a pivotal role in the research of inflammation and autoimmune disorders, including those related to lupus diseases. |
| In vitro | β-Aminoarteether（SM934；10 μM；24小时）处理在IFN-γ刺激下直接增强了初级腹膜巨噬细胞中的IL-10产生，并抑制了IL-12/23p40的产生[1]。在体外，β-Aminoarteether（SM934）能够抑制Th1和Th17的极化，但对Treg的分化没有影响[1]。 |
| In vivo | β-Aminoarteether（SM934；1-10 mg/kg；口服；每天；持续3个月）处理显著延缓了NZB/W F1小鼠肾小球肾炎的进展，提升了生存率。此外，β-Aminoarteether处理还促进了NZB/W F1小鼠巨噬细胞产生IL-10。【1】。动物模型：雌性NZB/W F1小鼠（六个半月龄）【1】。剂量：1 mg/kg、3 mg/kg、和10 mg/kg。给药方式：口服；每天；持续3个月。结果：显著延缓了肾小球肾炎的进展，并增加了NZB/W F1小鼠的生存率。 |
| Synonyms | β-Aminoarteether, SM934 free base |
| molecular weight | 327.42 |
| Molecular formula | C17H29NO5 |
| CAS | 133162-24-0 |
| Storage | |Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 60 mg/mL (183.25 mM) |
| References | 1. Li-Fei Hou, et al. SM934 treated lupus-prone NZB × NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One. 2012;7(2):e32424. |